Download presentation
Presentation is loading. Please wait.
1
Liver Transplantation at SLEH/BCM John A. Goss, MD Professor of Surgery
Michael E. DeBakey Department of Surgery Baylor College of Medicine Houston, Texas
2
History of Transplantation
1902 1983 1963 1936 1954 2002 1998 1994 1989 First attempt at kidney transplant First attempt at kidney transplant with human kidney First pediatric living donor liver transplant Cyclosporine FDA approved First liver transplant First successful kidney transplant First US adult living donor liver transplant Tacrolimus FDA approved MELD implemented
3
Initial Kidney Transplant Attempts:
Year Location Surgeon Procedure 1902 Lyon Alex Carrel Dog kidney tx into dog neck Vienna Emerich Ulmann Dog kidney tx into goat 1906 Mathieu Jaboulay Pig kidney tx into antecubital fossa 1909 Berlin Ernest Unger Monkey kidney tx into thigh 1936 Kherson Yu Voronoy First kidney tx using cadaveric human donor 1954 Boston Joseph Murray First successful kidney tx 1956 First tx using immunosuppression
4
First Successful Kidney Transplant
5
Experimental Liver Transplantation
text
6
Initial Liver Transplant Attempts: 1963-1964
No. Location Age Disease Survival Death 1 Denver 3 BA 0 days hemorrhage 2 48 HCC 22 days sepsis, PE 68 7 days 4 52 6 days liver failure 5 Boston 58 mets. 11 days sepsis 6 29 23 days 7 Paris 75
7
Initial Liver Transplant Attempts:
8
First Liver Transplant
March 1, 1963: First attempted human liver transplant July 23, 1967: First successful human liver transplant
9
Post-Moratorium Successes
anti-lymphocyte globulin (ALG) & the “triple cocktail” improved organ preservation definition of “brain death” text Starzl TE. J Am Coll Surg 2002; 195:587.
10
1968 Ad Hoc Committee of Harvard Medical School Published Criteria for Brain Death
1968 Uniform Anatomical Gift Act 1978 Uniform Brain Death Act 1983 NIH Consensus Development Conference: “…Liver Transplantation is a therapeutic modality for end stage liver disease that deserves broader application.” 1984 National Organ Transplant Act: Sale of organs prohibited Development of UNOS
11
Indications for Liver Transplant
Life-threatening and progressive irreversible liver disease Fulminant hepatic failure Hepatopulmonary or hepatorenal syndrome Worsening synthetic function Ascites resistant to medical therapy Hepatic encephalopathy Variceal hemorrhage Progressive malnutrition Increasing fatigue that interferes with daily activities Recurrent cholangitis Development of hepatocellular carcinoma
12
Etiology of Liver Disease
13
Indication for Liver Transplantation
Evaluation Process Hepatologist Transplant Surgeon Cardiologist Nurse Coordinator Social Worker Laboratory Studies Imaging (CT or MRI) List for Transplant Absolute Contraindications Uncontrolled systemic infection Extra-hepatic malignancies Ongoing drug or alcohol use Inability to comply with post-transplant therapy Relative Contraindications Portal vein thrombosis Pulmonary hypertension Cholangiocarcinoma HIV Medical Management
14
Liver Waitlist
15
Organ Allocation 2002-present
Timing of Transplant Organ Allocation 2002-present MELD (Model of End Stage Liver Disease) Originally developed to evaluate mortality in patients undergoing elective TIPS procedures Subsequently validated as predictive of survival in patients with end stage liver disease 85% of time accurately predicts individuals survival Only objective data used in calculation
16
MELD MELD 3 Month Mortality <10 2-8% 10-19 6-29% 20-29 50-76% 30-39
R= (0.957 x Loge(creatinine mg/dl) x Loge(total bilirubin mg/dl) x Loge(INR) )) x 10 MELD 3 Month Mortality <10 2-8% 10-19 6-29% 20-29 50-76% 30-39 62-83% >40 100%
17
Liver Allocation Status IA Status IB Local MELD/PELD
Regional MELD/PELD National IA/IB National MELD/PELD
19
Deceased Donor Technique
20
Recipient Technique: Liver
21
Recipient Technique: Liver
22
Immunosuppression
23
Improvement in Patient Survival
Time After Transplantation (years)
24
Improvement in Allograft Survival
Time After Transplantation (years)
25
US Survival: Adult Liver
26
US Survival: Pediatric Liver
27
Liver Transplantation -
BCM initiated Recruitment in 1998 1 Hepatologist, 2 Surgeons, 1 Nurse Coordinator 1 Social Worker, 1 Financial Coordinator, HLA Blood Bank, etc. Development of Patient Care Protocols – ICU, Anesthesia, OR Nurse Obtainment of UNOS Certification 6/98
28
Liver Transplantation -
Opened program 7/1/98 – combined with pediatric program at Texas Children’s Hospital 1st resection 7/5/98 1st liver transplant 9/2/98 9 liver transplants in All patients survived with 14 day length of stay
29
Liver Transplantation-
17 Physicians - 9 Adult Hepatologists 6 Pediatric Hepatologists 2 Surgeons 14 Nurse Coordinators 5 Hepatology Nurses 5 Medical Assistants 2 Administrative Staff 3 Transplant programs
30
SLEH Liver Transplant Team
SLEH/BCM Administration Margaret Van Bree, MHA, DrPH Paul Klotman, MD Todd Rosengart, MD Rachel Goldsmith, MPA Diesa Samp, BSN, RN, CCTC Physicians John Goss – BCM Blaine Hollinger-BCM Khozema Hussein-BCM Prasun Jalal-BCM Saira Khaderi-BCM Charles Phan-BCM Christine O’Mahony- BCM Gagan Sood, BCM Rise Stribling- BCM Norman Sussman-BCM John Vierling- BCM THI Anesthesiology C. David Collard, MD Cardiology Sayeed Feghali, MD THI Pathology/Blood Bank/ Lab Med Rhonda Shannon, MD Psychiatry Jennifer Pate, M.D. Pulmonary, Nephrology, Infectious Diseases, GI THI Nurse Coordinators Claudette Campbell, RN Jeanette Cleveland, RN Shannon Cook, RN Norma Flores, RN Felicia Franco, RN Diana Gonzalez, RN Demetrice Gray, RN Yolanda Murray, RN Wanda Samuels, RN Tamara Stephens, RN Pharmacy Raymond Yau, PharmD Social Work Ann Holder, LCSW Robin Kremer, LCSW Dietary Amy Cook, RD Financial Deidra Lester Exercise Physiologist Fabian Nursing Staff: CVOR, CV Recovery, 8CB 12 & 7 Tower
31
Diagnosis
32
Primary Payor 15% 33% 3% 48%
33
Transplant Totals 120 114 110 105 105 119 95 94 85 83 73 66 66 67 51 12
34
2010: One Thousand Liver Transplants
2010 Adult Liver Transplant Team
35
Patient Survival
36
* * * *Statistically higher than expected Graft Survival
37
2012 Summary Unadjusted patient and graft survival: 98%
Median length of stay: 9 days Operative time: 3 hours and 20 minutes Number of blood transfusions: 1.7 units of PRBCs
38
Future Directions Asian Liver Center Outreach clinics
Improvement in length of stay Improvement in survival Telemedicine/ECHO
40
Liver Transplantation – Education/Research
Provide Clinical Environment for BCM 3rd Year Medical Student and BCM General Surgery Residents TSMBE and ASTS Approved Liver Transplant Fellowship AASLD Funded NP Fellowship Trained Murat Kilic, MD – Chief of Liver Transplantation Izmir, Turkey 108 Peer-reviewed publications 102 National oral presentations TSMBE/ACGME Hepatology Fellowship
41
Liver Transplant Division: Ongoing Research Projects
Research Division Post-transplant Lymphoma Hepatocellular carcinoma Clinical Research
42
Status of Tissue Bank >1400 tissue samples from 146 patients
Sanger Sequencing of HCC Samples 300 amplicons over 30 genes 89 HCC samples with matched non tumor tissue or blood 33 HCV, 3 EtOH, 1 BA, 49 HBV, 3 with no underlying liver disease 16 Hepatoblastoma with non tumor tissue 4 Hepatic adenoma with non tumor tissue
43
Ongoing Projects Epigenetics of HCC Gene expression profiling
Investigating differential methylation patterns in tumor and non tumor tissue Gene expression profiling Developing cDNA libraries from mRNA Whole genome sequencing Select patients to have entire genome sequenced Testing new platforms New Next Generation sequencers to be tested on HCC samples Development of collaborative tissue exchange programs Vanderbilt, Baylor Dallas, Harvard, and Mayo Clinic participating in the early stages of the development of an HCC consortium
44
Future Reduce Donor/Recipient Discrepancy Donor awareness campaigns
Extended criteria/ asystolic donors Split liver transplantation Living-donor liver transplantation Xenotransplantation
45
Future Bioartificial Liver Stem Cells
46
Future Tolerance
47
Future Personalized Immunosuppression
Increase selectivity, decrease toxicity/side effects Pediatric transplantation Hepatitis C Coinfection
48
Future Pharmacogenetics and Pharmacogenomics
49
Future Primary Liver Tumors
Hepatocellular carcinoma that exceeds Milan Criteria Down-staging Presence of vascular invasion Genetics Choangiocarcinoma Previously considered a contraindication to OLT Mayo Protocol: multimodality neoadjuvant therapy
50
Conclusion Liver transplantation has produced a positive impact on patients with advanced liver disease Spectacular improvement have occurred since the preliminary work of Dr. Starzl The advances in liver transplantation have occurred in a short 45 years and provide a base for future advances
Similar presentations
